Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

467.800
-19.200-3.94%
Volume:180.24K
Turnover:84.62M
Market Cap:111.80B
PE:-282.35
High:500.000
Open:500.000
Low:459.000
Close:487.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.80
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.657
ROE:2.92%
ROA:-0.04%
PB:17.90
PE(LYR):-282.35
PS:45.81

Loading ...

Movement Alert|SKB BIO Falls 3.45% in Regular Trading, Biotech Sector Under Broad Selling Pressure

Market Focus
·
2 hours ago

Movement Alert|SKB BIO Rises 3.42% in Regular Trading, TROP2 ADC Sac-TMT Studies Selected as LBA at ESMO Conference Amid Sector Rally

Market Focus
·
Sep 30

SKB BIO: DFZQ Acquires Shares, Long Position Rises to 5.0%

HK Disclosure
·
Sep 29

Movement Alert|SKB BIO Rises 4.17% in Regular Trading, Multiple Studies Selected as Late-Breaking Abstracts at ESMO Plus Biotech Sector Resonance

Market Focus
·
Sep 29

SKB BIO (06990): 汇添富基金管理股份有限公司 Acquires Shares, Long Position Rises to 5.0%

HK Disclosure
·
Sep 24

Kelun-Biotech Says Phase 3 OptiTROP-Lung06 Sacituzumab Tirumotecan Plus Pembrolizumab Trial Wins ESMO 2026 Late-Breaker Slot

Reuters
·
Sep 22

Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Stock News
·
Sep 21

HK Movers | Innovative Drug Stocks Rally Broadly; LEPU BIO, INNOCARE, AKESO Jump Over 7%

Tiger Newspress
·
Sep 21

Movement Alert|SKB BIO Rises 3.34% in Regular Trading, Buoyed by First-Half Profitability Milestone and Pipeline Progress

Market Focus
·
Sep 21

DFZQ disposes 15,100 shares of SKB BIO

HK Disclosure
·
Sep 17

SKB BIO: 汇添富基金管理股份有限公司 Disposes of Shares, Long Position Falls to 4.99%

HK Disclosure
·
Sep 16

Hong Kong Stock Market Update: SKB Bio Surges Over 3% Following Positive Phase 2 Trial Results and Initiation of Phase 3 Study

Stock News
·
Sep 14

Kelun-Biotech Says Phase III Trial Shows Trastuzumab Botidotin Extends PFS vs T-DM1 in HER2+ Metastatic Breast Cancer

Reuters
·
Sep 14

SKB Biopharma's Partner Sees Positive Results from Asthma Drug Trial

MT Newswires Live
·
Sep 08

SKB BIO Announces Positive Phase 2 Interim Data and Phase 3 Launch for Asthma Antibody SKB378/WIN378

Bulletin Express
·
Sep 08

SKB BIO's Asthma Drug Shows Positive Phase 2 Results, Moving to Phase 3

Stock News
·
Sep 08

Sichuan Kelun-Biotech Biopharmaceutical Co - Second Phase 3 Trial Polaris-2 Planned to Begin in First Half of 2027

THOMSON REUTERS
·
Sep 08

Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of Skb378/Win378 in Asthma, and Initiates Phase 3 Study

THOMSON REUTERS
·
Sep 08

Sichuan Kelun-Biotech Biopharmaceutical Co - Skb378/Win378 Well Tolerated with no Treatment-Related Serious Adverse Events

THOMSON REUTERS
·
Sep 08

Sichuan Kelun-Biotech Biopharmaceutical Co - Windward Bio Initiates Phase 3 Study of Skb378/Win378 with Two Twice-Yearly Doses

THOMSON REUTERS
·
Sep 08